Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Challa S. S. R. Kumar and Faruq Mohammad. Abstract: Previous reviews focused on magnetic fluid hyperthermia using mono metallic/metal oxide nanoparticles. The term "hyperthermia" was limited to heat-based therapy. Recent studies show that magnetic nanoparticle-based hyperthermia can generate local heat for drug release. This review broadens the definition of hyperthermia to include thermotherapy and magnetically modulated drug delivery. It classifies controlled drug delivery into hyperthermia-based controlled drug delivery through bond breaking (DBB) and hyperthermia-based controlled drug delivery through enhanced permeability (DEP). The review also covers core-shell magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. The article highlights the potential of combining hyperthermia-based therapy and controlled drug release for personalized medicine. Keywords: Hyperthermia; hyperthermia-based therapy; hyperthermia-based controlled drug delivery; core-shell magnetic nanoparticles; theranostics. Hyperthermia is the use of heat to treat cancer. It can be classified into local, regional, and whole body hyperthermia. Traditional hyperthermia methods have limitations, such as heating healthy tissue and limited penetration. Magnetic materials for hyperthermia were first proposed in 1957. Magnetic nanoparticles (MNPs) offer advantages over traditional methods, such as targeted delivery and efficient heating. MNPs can cross the blood-brain barrier and are used for brain tumor treatment. MNPs can also be used for controlled drug delivery, with the first such nano construct made using layer-by-layer self-assembly. MNPs are used for hyperthermia-based therapy and controlled drug delivery. The mechanism of magnetic nanomaterials-based hyperthermia involves the conversion of magnetic energy into heat. The absorption efficiency is measured by specific absorption rate (SAR) or specific loss power (SLP). MNPs are more efficient than micrometric particles in converting magnetic energy into heat. The heating mechanism can be attributed to two phenomena: relaxation and hysteresis loss. The internal (Néel) and external (Brownian) sources of friction lead to thermal losses. The heating capacity of MNPs is governed by the induction of rapid variation of magnetic moments. MNPs are used for hyperthermia-based controlled drug delivery. Two mechanisms are discussed: hyperthermia-based controlled drug delivery through bond breaking (DBB) and hyperthermia-based controlled drug delivery through enhanced permeability (DEP). DBB involves the release of drugs due to heating of the linker molecule attached to the NP's surface. DEP involves the release of drugs from within a polymeric matrix due to local heat generated by the MNPs. The release of drugs can be due to the creation of nanocrevices or cracks in the polymeric matrix. MNPs are used for hyperthermia-based therapy.Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Challa S. S. R. Kumar and Faruq Mohammad. Abstract: Previous reviews focused on magnetic fluid hyperthermia using mono metallic/metal oxide nanoparticles. The term "hyperthermia" was limited to heat-based therapy. Recent studies show that magnetic nanoparticle-based hyperthermia can generate local heat for drug release. This review broadens the definition of hyperthermia to include thermotherapy and magnetically modulated drug delivery. It classifies controlled drug delivery into hyperthermia-based controlled drug delivery through bond breaking (DBB) and hyperthermia-based controlled drug delivery through enhanced permeability (DEP). The review also covers core-shell magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. The article highlights the potential of combining hyperthermia-based therapy and controlled drug release for personalized medicine. Keywords: Hyperthermia; hyperthermia-based therapy; hyperthermia-based controlled drug delivery; core-shell magnetic nanoparticles; theranostics. Hyperthermia is the use of heat to treat cancer. It can be classified into local, regional, and whole body hyperthermia. Traditional hyperthermia methods have limitations, such as heating healthy tissue and limited penetration. Magnetic materials for hyperthermia were first proposed in 1957. Magnetic nanoparticles (MNPs) offer advantages over traditional methods, such as targeted delivery and efficient heating. MNPs can cross the blood-brain barrier and are used for brain tumor treatment. MNPs can also be used for controlled drug delivery, with the first such nano construct made using layer-by-layer self-assembly. MNPs are used for hyperthermia-based therapy and controlled drug delivery. The mechanism of magnetic nanomaterials-based hyperthermia involves the conversion of magnetic energy into heat. The absorption efficiency is measured by specific absorption rate (SAR) or specific loss power (SLP). MNPs are more efficient than micrometric particles in converting magnetic energy into heat. The heating mechanism can be attributed to two phenomena: relaxation and hysteresis loss. The internal (Néel) and external (Brownian) sources of friction lead to thermal losses. The heating capacity of MNPs is governed by the induction of rapid variation of magnetic moments. MNPs are used for hyperthermia-based controlled drug delivery. Two mechanisms are discussed: hyperthermia-based controlled drug delivery through bond breaking (DBB) and hyperthermia-based controlled drug delivery through enhanced permeability (DEP). DBB involves the release of drugs due to heating of the linker molecule attached to the NP's surface. DEP involves the release of drugs from within a polymeric matrix due to local heat generated by the MNPs. The release of drugs can be due to the creation of nanocrevices or cracks in the polymeric matrix. MNPs are used for hyperthermia-based therapy.